"10.1371_journal.pone.0044694","plos one","2012-09-26T00:00:00Z","Kasinath Viswanathan; Ilze Bot; Liying Liu; Erbin Dai; Peter C Turner; Babajide Togonu-Bickersteth; Jakob Richardson; Jennifer A Davids; Jennifer M Williams; Mee Y Bartee; Hao Chen; Theo J C van Berkel; Erik A L Biessen; Richard W Moyer; Alexandra R Lucas","Vascular Biology Research Group, Robarts Research Institute, London, Canada; Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands; University of Maastracht, Maastracht, The Netherlands; Department of Medicine, Divisions of Cardiovascular Medicine and Rheumatology, University of Florida, Gainesville, Florida, United States of America; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States of America","Conceived and designed the experiments: KV IB PCT LYL ED RWM EALB TJCvB ARL. Performed the experiments: KV IB LYL ED EALB PCT RM JMW JAD HC JR BTB ARL. Analyzed the data: KV IB LYL ED EB RWM JMW JAD BTB JR MYB ARL. Contributed reagents/materials/analysis tools: KV IB LYL ED EB PCT RM JMW JAD BTB JR MYB TJCvB ARL. Wrote the paper: KV IB LYL ED EB PCT RM JMW JAD BTB JR MYB TJCvB ARL.","ARL is the chief clinical officer and holds shares in a small Biotechnology company, Viron Therapeutics, Inc in London, Canada, which is developing another viral serpin for clinical use. The cross-class serpins in this paper have different molecular targets and are not in any way connected to, nor under development by, this biotech company. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","09","Kasinath Viswanathan","KV",15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
